Skip to main content

Table 7 SF-36 pain scale scores by group and visit

From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

   Group P value(Between Groups)
Visit   UP446
250 mg/day
UP446
500 mg/day
Celecoxib
200 mg/day
Placebo  
Baseline Mean 8.53 7.53 8.20 7.40 0.272
  Std Deviation 1.85 2.17 1.86 1.24  
30 Days Mean 7.53 7.67 8.46 7.33 0.325
  Std Deviation 1.41 1.95 .97 2.06  
60 Days Mean 7.29 7.38 8.08 7.31 0.643
  Std Deviation 1.49 2.06 1.93 1.80  
90 Days Mean 7.50 6.54 7.50 7.54 0.547
  Std Deviation 2.03 1.98 2.50 1.76